➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Colorcon
Mallinckrodt
Dow
McKesson

Last Updated: October 30, 2020

DrugPatentWatch Database Preview

NASONEX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Nasonex, and what generic alternatives are available?

Nasonex is a drug marketed by Merck Sharp Dohme and is included in one NDA.

The generic ingredient in NASONEX is mometasone furoate. There are thirty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.

US ANDA Litigation and Generic Entry Outlook for Nasonex

A generic version of NASONEX was approved as mometasone furoate by PERRIGO NEW YORK on March 18th, 2002.

  Start Trial

Drug patent expirations by year for NASONEX
Drug Prices for NASONEX

See drug prices for NASONEX

Drug Sales Revenue Trends for NASONEX

See drug sales revenues for NASONEX

Recent Clinical Trials for NASONEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Washington University School of MedicinePhase 4
EMSPhase 3
NasalezePhase 4

See all NASONEX clinical trials

Pharmacology for NASONEX
Paragraph IV (Patent) Challenges for NASONEX
Tradename Dosage Ingredient NDA Submissiondate
NASONEX SPRAY, METERED;NASAL mometasone furoate 020762 2009-08-07

US Patents and Regulatory Information for NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997   Start Trial   Start Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997   Start Trial   Start Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997   Start Trial   Start Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for NASONEX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0057401 94C0004 Belgium   Start Trial PRODUCT NAME: MOMETASONI FUROAS; NAT REG.: 304 S 133 F 7 19930813; FIRST REG.: GR 10682/89 19900622
0548114 19875032 Germany   Start Trial PRODUCT NAME: MOMETASON-FUROAT-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 40803.00.00 19980218; FIRST REGISTRATION: FRANKREICH NL 22055 19970219
0548114 C980012 Netherlands   Start Trial PRODUCT NAME: MOMETASONI FUROAS MONOHYDRATUM; NAT. REGISTRATION NO/DATE: RVG 21613 19971209; FIRST REGISTRATION: FR NL22055 19970219
0548114 980012 Netherlands   Start Trial 980012, 20110905, EXPIRES: 20160905
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Harvard Business School
Moodys
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.